Table 1 Comparison of Baseline Characteristics Between the Training and Validation Sets
Variables | Total (n = 277) | Training set (n = 193) | Validation Set (n = 84) | P value |
|---|---|---|---|---|
Sex, n (%) | 0.704 | |||
 Female | 83 (30) | 56 (29) | 27 (32.1) | |
 Male | 194 (70) | 137 (71) | 57 (67.9) | |
Age, Mean ± SD | 56.4 ± 10.5 | 56.1 ± 10.7 | 57 ± 10 | 0.509 |
BMI, Median (Q1, Q3) | 21 (19.6, 23.5) | 21.1 (19.8, 23.7) | 20.8 (19.4, 22.9) | 0.319 |
WBC, Median (Q1, Q3) | 6.2 (5, 7.7) | 6.3 (5.2, 7.7) | 6 (5, 7.7) | 0.472 |
RBC, Median (Q1, Q3) | 116 (93, 132) | 117 (96, 133) | 115 (91, 129.2) | 0.337 |
PLT, Median (Q1, Q3) | 280 (236, 351) | 290 (237, 347) | 270.5 (232, 381.2) | 0.928 |
NEUT, Median (Q1, Q3) | 3.7 (3, 4.9) | 3.7 (3, 4.9) | 3.6 (2.8, 4.7) | 0.507 |
MONO, Median (Q1, Q3) | 0.4 (0.3, 0.6) | 0.5 (0.3, 0.6) | 0.4 (0.3, 0.6) | 0.638 |
LYMPH, Median (Q1, Q3) | 1.7 (1.3, 2.1) | 1.6 (1.3, 2) | 1.7 (1.4, 2.1) | 0.807 |
D-Dimer, Median (Q1, Q3) | 0.4 (0.2, 0.9) | 0.3 (0.1, 0.8) | 0.4 (0.2, 1) | 0.051 |
CEA, Median (Q1, Q3) | 2.4 (1.5, 5.1) | 2.3 (1.5, 4.7) | 3 (1.6, 5.8) | 0.102 |
CA199, Median (Q1, Q3) | 10.3 (3.1, 31.3) | 10.7 (3.2, 31.3) | 8.9 (2.7, 29.5) | 0.771 |
CA125, Median (Q1, Q3) | 11.6 (8, 19.1) | 11.6 (8, 20.1) | 11.7 (7.6, 17.5) | 0.681 |
AFP, Median (Q1, Q3) | 2.6 (1.8, 3.9) | 2.6 (1.8, 3.8) | 2.5 (1.7, 4) | 0.542 |
ALB, Median (Q1, Q3) | 36.8 (34.4, 39.7) | 36.8 (34.3, 39.5) | 37.2 (34.6, 40.3) | 0.346 |
Clinical T stage, n (%) | 0.883 | |||
 T2-3 | 84 (30.3) | 60 (31.1) | 24 (28.6) | |
 T4a | 162 (58.5) | 111 (57.5) | 51 (60.7) | |
 T4b | 31 (11.2) | 22 (11.4) | 9 (10.7) | |
Clinical N stage, n (%) | 0.681 | |||
 N0 | 37 (13.4) | 27 (14) | 10 (11.9) | |
 N1 | 70 (25.3) | 52 (26.9) | 18 (21.4) | |
 N2 | 101 (36.5) | 67 (34.7) | 34 (40.5) | |
 N3 | 69 (24.9) | 47 (24.4) | 22 (26.2) | |
Gross location, n (%) | 0.698 | |||
 Upper portion | 89 (32.1) | 65 (33.7) | 24 (28.6) | |
 Middle portion | 77 (27.8) | 52 (26.9) | 25 (29.8) | |
 Lower portion | 111 (40.1) | 76 (39.4) | 35 (41.7) | |
Anatomic location, n (%) | 0.287 | |||
 Gastric antrum | 110 (39.7) | 76 (39.4) | 34 (40.5) | |
 Gastric body | 74 (26.7) | 51 (26.4) | 23 (27.4) | |
 Cardia | 62 (22.4) | 48 (24.9) | 14 (16.7) | |
 Gastric fundus or angle | 31 (11.2) | 18 (9.3) | 13 (15.5) | |
Lauren classification, n (%) | 0.412 | |||
 Intestinal type | 92 (33.2) | 62 (32.1) | 30 (35.7) | |
 Mixed type | 49 (17.7) | 38 (19.7) | 11 (13.1) | |
 Diffuse type | 136 (49.1) | 93 (48.2) | 43 (51.2) | |
Pathological grade, n (%) | 0.212 | |||
 Othersa | 106 (38.3) | 79 (40.9) | 27 (32.1) | |
 Poorly differentiated | 171 (61.7) | 114 (59.1) | 57 (67.9) | |
nNAC, n (%) | 0.417 | |||
 2 | 40 (14.4) | 28 (14.5) | 12 (14.3) | |
 3 | 53 (19.1) | 33 (17.1) | 20 (23.8) | |
 4 | 184 (66.4) | 132 (68.4) | 52 (61.9) | |
Immunotherapy, n (%) | 0.824 | |||
 No | 202 (72.9) | 142 (73.6) | 60 (71.4) | |
 Yes | 75 (27.1) | 51 (26.4) | 24 (28.6) | |
Radscore, Median (Q1, Q3) | 0 (-0.1, 0.1) | 0 (-0.1, 0.1) | 0 (-0.1, 0.1) | 0.763 |
LN retrieval, n (%) | 0.742 | |||
 LN (-) | 141 (50.9) | 100 (51.8) | 41 (48.8) | |
 LN (+) | 136 (49.1) | 93 (48.2) | 43 (51.2) |